On April 1, 2024, Sutro Biopharma, a NASDAQ-listed American company, and the renowned French pharmaceutical company Ipsen, entered into a global exclusive licensing agreement. The agreement covers Sutro's investigational ADC (Antibody-Drug Conjugate) candidate, STRO-003. Under the terms of the deal, Ipsen will make an upfront payment of $90 million to Sutro and potentially pay up to $900 million in milestone payments. This is Ipsen's first major investment in the ADC field.
STRO-003 is a next-generation ADC targeting ROR1 (Receptor Tyrosine Kinase-Like Orphan Receptor 1). This ADC uses exatecan (iexabepilone) as the payload, delivered through a β-glucuronidase-cleavable linker. In addition to STRO-003, Sutro has other ADC candidates in clinical development, including FRa ADC and CD74ADC, as well as TF ADC in preclinical stages. The company is also collaborating with Astellas on immunostimulatory ADCs (iADCs) in preclinical research.
This transaction not only highlights the immense potential of ADC technology in targeted cancer therapy, but also reflects the intense competition among domestic and international pharmaceutical companies in this field. A thorough analysis of the current clinical and market landscape of ROR1 ADCs will help us better understand the future development trends of innovative medicines.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.